Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: SG who wrote (11614)	10/21/2012 9:04:09 AM
From: NTTG	3 Recommendations Read Replies (1) \| Respond to of 13111

SG...Not sure who your comment was directed to, hopefully not me. I think it is tragic that investors can not see any evidence (human or animal model) of how PV-10 compares to other treatment options in 2012.... Having to wait till 2017+ is simply unbelievable. Adding insult to injury, it has been a long time since the company has followed up on their initial announcement of dermatology work (where will this data be presented for review), and floats the unfortunate rumor that RB should be studied in pancreatic cancer. To the later point, pancreatic cancer is a particularly aggressive disease that needs to be caught and managed early...having to wait for a tumor mass to grow big enough that it can be injected is not an attractive approach, and we already know that RB does not work well in rapidly progressing disease. The company has bailed on breast cancer work for the same reason.... I think the plan is to keep investor eyes 'drifting' from topic to topic so they don't dwell on underperformance. Next time MGT is in NYC for their next Maxim investor conference they should take a moment to visit the street artists who run 'find the pea' games on folding card tables, they need to hone these skills too.